Pharmakokinetics of Mistletoe Lectins after Intravenous Application of a Mistletoe Product in Healthy Subjects
Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacokinetics are widely lacking. Therefore, the aim of...
Saved in:
Main Authors: | Ann-Kathrin Lederer (Author), Sabine Rieger (Author), Michael Schink (Author), Roman Huber (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer
by: Roman Huber, et al.
Published: (2017) -
Mistletoe lectins: From interconnecting proteins to potential tumour inhibiting agents
by: Mahak Majeed, et al.
Published: (2021) -
The Mistletoe Bough
by: Trollope, Anthony, 1815-1882 -
The Bride of the Mistletoe
by: Allen, James Lane, 1849-1925 -
Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities
by: Michael Schink, et al.
Published: (2017)